Anteris technologies announces one-year clinical outcomes for duravr® thv to be presented at tct® 2025

Minneapolis and brisbane, australia, oct. 27, 2025 (globe newswire) -- anteris technologies global corp. (anteris or the company) (nasdaq: avr, asx: avr), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced that one-year clinical outcomes with the duravr® transcatheter heart valve (thv) will be presented by rishi puri md phd, at tct® 2025 – the 37th annual transcatheter cardiovascular therapeutics® conference, taking place in san francisco, california, october 25-28, 2025.
AVR Ratings Summary
AVR Quant Ranking